Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (ATNM) yesterday and set a price target of $1.50. The company’s shares opened today at $0.27, close to its 52-week low of $0.23.
McCarthy observed:
“Actinium announced that the 75 th person in the pivotal Phase 3 SIERRA trial has been enrolled and dosed with Iomab-B for end-stage acute myeloid leukemia (AML); 50% of enrollment.”
According to TipRanks.com, McCarthy has 0 stars on 0-5 star ranking scale with an average return of -21.1% and a 24.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Aridis Pharmaceuticals Inc, and Achieve Life Sciences Inc.
Actinium Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $2.75, a 905.5% upside from current levels. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $4 price target.
See today’s analyst top recommended stocks >>
Based on Actinium Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $5.67 million. In comparison, last year the company had a GAAP net loss of $4.86 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells.
